Role of microalbuminuria in the assessment of cardiovascular risk in essential hypertension

Journal of the American Society of Nephrology

Volumn 16, Issue 3 SUPPL. 1, 2005, Pages

  Pontremoli, Roberto ^a   Leoncini, Giovanna ^a   Viazzi, Francesca ^a   Parodi, Denise ^a   Vaccaro, Valentina ^a   Falqui, Valeria ^a   Parodi, Angelica ^a   Vettoretti, Simone ^a   Ratto, Elena ^a   Deferrari, Giacomo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; LOSARTAN; BIOLOGICAL MARKER;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; ESSENTIAL HYPERTENSION; HUMAN; MICROALBUMINURIA; PRIORITY JOURNAL; RISK ASSESSMENT; ALBUMINURIA; CARDIOVASCULAR DISEASE; COMORBIDITY; COMPARATIVE STUDY; DISEASE COURSE; FEMALE; HOSPITALIZATION; HYPERTENSION; KIDNEY FUNCTION TEST; MALE; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY;

ALBUMINURIA; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; KIDNEY FUNCTION TESTS; MALE; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 20844437554     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004110955     Document Type: Conference Paper

References (15)

1. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodriguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescio F: Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289: 2363-2369, 2003
2. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giam-paoli S, Joffres MR, Poulter N, Primatesta P, Stegmayr B, Thamm M: Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 43: 10-17, 2004
3. European Society of Hypertension-European Society of Cardiology Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21: 1011-1053, 2003
4. Ogden LG, He J, Lydick E, Whelton PK: Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 35: 539-543, 2000
5. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383-393, 2003
6. Pontremoli R: Microalbuminuria in essential hypertension-Its relation to cardiovascular risk factors. Nephrol Dial Transplant 11: 2113-2115, 1996
7. Pontremoli R, Ravera M, Bezante GP, Viazzi F, Nicolella C, Berruti V, Leoncini G, Del Sette M, Brunelli C, Tomolillo C, Deferrari G: Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. J Hypertens 17: 993-1000, 1999
8. Leoncini G, Sacchi G, Ravera M, Viazzi F, Ratto E, Vettoretti S, Parodi D, Bezante GP, Del Sette M, Deferrari G, Pontremoli R: Microalbuminuria is an integrated marker of subclinical organ damage in primary hypertension. J Hum Hypertens 16: 399-404, 2002
9. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K: Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 35: 898-903, 2000
10. Devereux RB, Alderman MH: Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation 88: 1444-1455, 1993
11. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P: Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Ann Intern Med 139: 901-906, 2003
12. Olsen MH, Wachtell K, Borch-Johnsen K, Okin PM, Kjeldsen SE, Dahlof B, Devereux RB, Ibsen HA: Blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE Study. Losartan Intervention For Endpoint reduction. J Hum Hypertens 16: 591-595, 2002
13. Leoncini G, Sacchi G, Viazzi F, Ravera M, Parodi D, Ratto E, Vettoretti S, Tomolillo C, Deferrari G, Pontremoli R: Microalbuminuria identifies overall cardiovascular risk in essential hypertension: An artificial neural network-based approach. J Hypertens 20: 1315-1321, 2002
14. Volpe M, Cosentino F, Ruilope LM: Is it time to measure microalbuminuria in hypertension? J Hypertens 21: 1213-1220, 2003
15. Viazzi F, Parodi D, Leoncini G, Vettoretti S, Ratto E, Vaccaro V, Ravera M, Tomolillo C, Bezante GP, Del Sette M, Deferrari G, Pontremoli R: Optimizing global risk evaluation in primary hypertension: The role of microalbuminuria and cardiovascular ultrasonography. J Hypertens 22: 1-7, 2004